Biomarkers in Severe Asthma

Wan, Xiao Chloe; Woodruff, Prescott G.

doi:10.1016/j.iac.2016.03.004

Cited by 48 publications

(59 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgE, eosinophil count, the fraction of exhaled nitric acid, and periostin (POSTN, or osteoblast-specific factor; OSF-2) has turned up to be some habitual asthma biomarkers. The potential use of biomarkers in asthma includes its diagnosis, finding out the severity of the disease, defining disease endotype, possible treatment measures, treatment response, reduce the risk of disease exacerbation and inhibit the declining function of the lung [36] , [37] , [38] .…”

Section: Type-2 Inflammation In Asthmamentioning

confidence: 99%

A review on the effect of COVID-19 in type 2 asthma and its management

Ghosh¹,

Das

Mondal³

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

Section: Type-2 Inflammation In Asthmamentioning

confidence: 99%

A review on the effect of COVID-19 in type 2 asthma and its management

Ghosh¹,

Das

Mondal³

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…These markers should meet precise specifications and criteria such as reliability, ease of collection and measurement, and non-invasive. Using reliable biomarkers to predict asthma patients’ response to steroid therapy early in the disease course is particularly important and essential to have an optimal response and avoid undesirable side effects 3 . Using such biomarkers is not routinely requested in severe asthma 4 as the biomarkers most extensively studied at present in asthma are Th2 related biomarkers 5 .…”

Section: Introductionmentioning

confidence: 99%

Derangement of cell cycle markers in peripheral blood mononuclear cells of asthmatic patients as a reliable biomarker for asthma control

Hachim

Elemam

Ramakrishnan

et al. 2021

Sci Rep

View full text Add to dashboard Cite

In asthma, most of the identified biomarkers pertain to the Th2 phenotype and no known biomarkers have been verified for severe asthmatics. Therefore, identifying biomarkers using the integrative phenotype-genotype approach in severe asthma is needed. The study aims to identify novel biomarkers as genes or pathways representing the core drivers in asthma development, progression to the severe form, resistance to therapy, and tissue remodeling regardless of the sample cells or tissues examined. Comprehensive reanalysis of publicly available transcriptomic data that later was validated in vitro, and locally recruited patients were used to decipher the molecular basis of asthma. Our in-silicoanalysis revealed a total of 10 genes (GPRC5A, SFN, ABCA1, KRT8, TOP2A, SERPINE1, ANLN, MKI67, NEK2, and RRM2) related to cell cycle and proliferation to be deranged in the severe asthmatic bronchial epithelium and fibroblasts compared to their healthy counterparts. In vitro, RT qPCR results showed that (SERPINE1 and RRM2) were upregulated in severe asthmatic bronchial epithelium and fibroblasts, (SFN, ABCA1, TOP2A, SERPINE1, MKI67, and NEK2) were upregulated in asthmatic bronchial epithelium while (GPRC5A and KRT8) were upregulated only in asthmatic bronchial fibroblasts. Furthermore, MKI76, RRM2, and TOP2A were upregulated in Th2 high epithelium while GPRC5A, SFN, ABCA1 were upregulated in the blood of asthmatic patients. SFN, ABCA1 were higher, while MKI67 was lower in severe asthmatic with wheeze compared to nonasthmatics with wheezes. SERPINE1 and GPRC5A were downregulated in the blood of eosinophilic asthmatics, while RRM2 was upregulated in an acute attack of asthma. Validation of the gene expression in PBMC of locally recruited asthma patients showed that SERPINE1, GPRC5A, SFN, ABCA1, MKI67, and RRM2 were downregulated in severe uncontrolled asthma. We have identified a set of biologically crucial genes to the homeostasis of the lung and in asthma development and progression. This study can help us further understand the complex interplay between the transcriptomic data and the external factors which may deviate our understanding of asthma heterogeneity.

show abstract

“…The biological molecules/chemicals that act as a putative diagnostic of asthma are either type-2 inflammation-related or type-2 inflammation-independent markers. [ 59 ] The type-2 inflammation-related markers are cytokine secreted by type-2 T helper cells such as interleukin-4, IL-5, and IL-13. In addition, eosinophil count in blood and sputum, fraction of elevated NO levels of breath and periostin levels in blood serum, and Dipeptidyl peptidase-4 in lung epithelia are also type-2 inflammation-related biomarkers for asthma.…”

Section: Diagnostic Biomarkersmentioning

confidence: 99%

“…In addition, eosinophil count in blood and sputum, fraction of elevated NO levels of breath and periostin levels in blood serum, and Dipeptidyl peptidase-4 in lung epithelia are also type-2 inflammation-related biomarkers for asthma. [ 59 ] The type-2 inflammation-independent markers includes interleukin-6, IL-17, C-reactive proteins, and neutrophil count in sputum.…”

Section: Diagnostic Biomarkersmentioning

confidence: 99%

An update on the diagnostic biomarkers for asthma

Pandey

Parkash

Kant

et al. 2021

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Asthma is a respiratory disorder accounts for ~339 million cases per annum. The initial diagnosis of asthma relies on the symptomatic identification of characters, such as wheeze, shortness of breath, chest tightness, and cough. The presence of two or more of these symptoms may be considered as indicative of asthma. The asthma-diagnostic also involves spirometry test before and after inhaling a bronchodilator like albuterol. Because asthma pathophysiology involves participation of immune system, the cytokines play an important role. The review discusses various molecules that are or may be used as biomarkers for the asthma diagnosis.

show abstract

Biomarkers in Severe Asthma

Cited by 48 publications

References 87 publications

A review on the effect of COVID-19 in type 2 asthma and its management

A review on the effect of COVID-19 in type 2 asthma and its management

Derangement of cell cycle markers in peripheral blood mononuclear cells of asthmatic patients as a reliable biomarker for asthma control

An update on the diagnostic biomarkers for asthma

Contact Info

Product

Resources

About